Navigation Links
Celtic Pharma Announces Issuance of U.S. Patent 7,816,323 for Xerecept® in Combination with Avastin® as a Treatment for Breast and Colon Cancers
Date:10/21/2010

ormer Chair of Neuro-Oncology at Memorial Sloan-Kettering Cancer Center commented, "The emerging data from the combination of Xerecept and Avastin is an important development that strongly suggests the need for evaluation of this combination treatment in patients.  Combination therapies are an important part of modern anticancer therapy.  The use of rational combinations of targeted, mechanism-based treatments offers the clinical oncologist the promise of more potent therapeutic options for addressing the multifaceted complexity of cancer."

Celtic Pharma is actively exploring clinical trial strategies to assess combination treatments of Xerecept with Avastin in order to validate these important preclinical findings in a clinical setting, and is also considering the potential for exploring Xerecept in combination with other leading cancer therapies. Celtic Pharma is in productive discussions with the U.S. Food and Drug Administration (FDA) in regards to the design of a registrational study evaluating objectively the clinical benefit associated with reductions in steroid dosing that may be achieved with the use of Xerecept in both primary and metastatic brain tumor patients. Celtic Pharma is also currently evaluating Xerecept in a pediatric trial for patients requiring high doses of corticosteroids to control their cerebral edema, with resulting heavy burdens of steroid-related symptoms.

Preclinical Studies

Several preclinical studies using implanted solid tumor (breast and colon) human xenografts into nude mice, as well as both pediatric and adult human brain tumor xenografts, were evaluated when treated with Xerecept® alone and in combination with Avastin®.  All of these particular models demonstrated statistically significant tumor regression and prolongation of survival following combination treatment with Xerecept and Avastin, compared to Xerecept or Avastin alone.

Specifically, in the human breast model
'/>"/>

SOURCE Celtic Pharmaceutical Holdings L.P.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Celtic Pharma Provides Update on XERECEPT(R) Clinical Program
2. Celtic Pharma Announces Update on Status of XERECEPT(R) Program Sale Planned in 2009
3. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
4. Celtic Pharma Announces Initiation of Pediatric Dose Tolerance Trial Evaluating XERECEPT(R) in Pediatric Patients with Primary and Metastatic Brain Tumors
5. Celtic Pharma Announces Initiation of Phase III Trial of TDT 067 for the Treatment of Onychomycosis
6. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
10. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
11. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... , Aug. 4, 2015 HeartWare ... innovator of less invasive, miniaturized circulatory support technologies that ... announced that its President and Chief Executive Officer, ... Canaccord Genuity 35th Annual Growth Conference at 8:30 a.m. ... being held August 12-13, 2015 at the InterContinental Boston. ...
(Date:8/4/2015)... 2015  The Pittsburgh Life Sciences Greenhouse (PLSG), the ... that one of its portfolio companies, Medrobotics Corporation, has ... Robotic System in the U.S.  ... Medrobotics," said John W. Manzetti , president and ... way since spinning out of The Robotics Institute at ...
(Date:8/4/2015)... Pharma Ltd. (the "Company") (NASDAQ: NTEC ), a ... on its proprietary Accordion Pill platform technology, today announced ... the United States of 5,025,000 of ... of $6.00 per ordinary share, before underwriting discounts and ... by the Company.  In addition, the Company has granted ...
Breaking Medicine Technology:HeartWare Presentation At The Canaccord Genuity 35th Annual Growth Conference To Be Webcast 2Pittsburgh Life Sciences Greenhouse Portfolio Client Medrobotics Receives FDA Market Clearance 2Pittsburgh Life Sciences Greenhouse Portfolio Client Medrobotics Receives FDA Market Clearance 3Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 2Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 3
(Date:8/4/2015)... , ... August 04, 2015 , ... Statement by Paul ... the introduction of the Mental Health Reform Act of 2015 by Senators ... mental health reform a reality in America. , “This legislation and H.R. ...
(Date:8/4/2015)... ... August 04, 2015 , ... assistPoint Partners, LLC is ... oncology patient assistance programs. Through a secure web portal, assistPoint connects Life Sciences, ... enterprise level, cloud-based application and workflow solution. This provides cancer center patient advocates, ...
(Date:8/4/2015)... ... August 04, 2015 , ... Healthy ... Origins® Cognizin® is a trademark for Citicoline, a nutrient that supports memory function ... those applications which have more of a semi-solid composition. Vegetarian capsules are ...
(Date:8/4/2015)... ... August 04, 2015 , ... It’s hard ... Medical & Day Spa in Santa Barbara, CA is offering the solution by ... that permanently eliminates sweat and odor glands in the underarms. This simple and ...
(Date:8/4/2015)... ... August 04, 2015 , ... Recent studies ... a rise in binge drinking among certain populations and specific locations. ... continuing to examine trends and evidence to help facilitate health care treatment to ...
Breaking Medicine News(10 mins):Health News:MHA Applauds Introduction of Mental Health Reform Act of 2015 2Health News:MHA Applauds Introduction of Mental Health Reform Act of 2015 3Health News:assistPoint.com Web Site Launched 2Health News:Healthy Origins® Introduces Cognizin® Citicoline in a Vegetarian Capsule 2Health News:Healthy Origins® Introduces Cognizin® Citicoline in a Vegetarian Capsule 3Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 3Health News:DARA Responds To International Trends in Binge Drinking 2Health News:DARA Responds To International Trends in Binge Drinking 3
... University of the Rockies (UoR) has introduced a ... master,s or doctoral degree in Psychology."As the demand ... an increasing need for professionals to administer the ... provided," said Dr. Steve Kirkpatrick, Dean of the ...
... Letter to Governors Rendell, Douglas Says to Use Medicaid ... Feb. 23 In a new letter to National ... Douglas (R-VT), the Coalition to Protect Senior Care (CPSC), ... today urged the nation,s Governors to ensure new state ...
... 23 Nostrum Pharmaceuticals, LLC ("Nostrum"), a privately-held ... that it has obtained a worldwide license to ... derivatives and analogues ("Caerulomycin") for their novel indication ... Institute of Microbial Technology ("IMTECH"), Chandigarh, India, one ...
... teamed up with world famous "Hippocrates Health Institute" with ... of HHI are now able to take advantage of ... the source of what many doctors and alternative health ... health problems including obesity, skin problems, and even cancer, ...
... Star Sabrina Bryan Will Visit SchoolLEOTI, Kan., Feb. 23 ... the economy. One challenge was that the junior high gymnasium ... the students with no place to exercise indoors during the ... high managed to rally support for their dedication to health ...
... March 12, 2009 - 9:00 a.m. ET HOPKINTON, Mass., ... CALP ) will conduct a conference call discussing ... a.m. ET on Thursday, March 12. Kevin Hrusovsky, ... Financial Officer, will host the call. Management will discuss ...
Cached Medicine News:Health News:University of the Rockies Introduces Mental Health Administration Specialization for Psych Majors 2Health News:National Caregiver Coalition to National Governors Association: Establish State Task Forces to Monitor Medicaid Spending, Ascertain Funds Going to Protect Seniors 2Health News:National Caregiver Coalition to National Governors Association: Establish State Task Forces to Monitor Medicaid Spending, Ascertain Funds Going to Protect Seniors 3Health News:Nostrum Pharmaceuticals Obtains Worldwide Licensing Rights From IMTECH for Clinical Development of the Small Molecule Caerulomycin and Its Proprietary Derivatives for Their Novel Indication of Immunosuppression 2Health News:Nostrum Pharmaceuticals Obtains Worldwide Licensing Rights From IMTECH for Clinical Development of the Small Molecule Caerulomycin and Its Proprietary Derivatives for Their Novel Indication of Immunosuppression 3Health News:LuxSauna Teams With World Famous Detox Health Retreat 'Hippocrates Health Institute' 2Health News:Leoti, Kan. Junior High Finds Ways to Exercise, Wins National Health Contest 2Health News:Leoti, Kan. Junior High Finds Ways to Exercise, Wins National Health Contest 3Health News:Leoti, Kan. Junior High Finds Ways to Exercise, Wins National Health Contest 4Health News:Caliper Life Sciences' Fourth Quarter 2008 Financial Results Conference Call Notice 2
All BioWhittaker Cell Culture Reagent and Buffer products are manufactured in accordance with cGMP regulations and are cell culture tested to assure compatibility. , Typical Properties, Sterility : ...
...
... sulfate is effective against gram positive and ... by interfering with bacterial protein synthesis by ... Its suggested working concentration of 50 mg/L ... cells, thereby making a gentler alternative to ...
Gentamicin Reagent Solution (10 mg/ml) liquid...
Medicine Products: